ICU Medical, Inc. (NASDAQ:ICUI) Receives $172.00 Consensus Target Price from Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has been given a consensus rating of “Buy” by the nine ratings firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $172.00.

A number of analysts recently commented on ICUI shares. KeyCorp upped their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st. Zacks Research raised ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Needham & Company LLC upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research note on Wednesday, May 27th. Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, Piper Sandler lowered their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th.

Insider Activity at ICU Medical

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Maryland State Retirement & Pension System grew its holdings in ICU Medical by 2.0% during the fourth quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier’s stock valued at $516,000 after purchasing an additional 70 shares during the period. California Public Employees Retirement System lifted its position in shares of ICU Medical by 0.3% during the 1st quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock valued at $3,934,000 after buying an additional 90 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of ICU Medical by 1.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock valued at $803,000 after buying an additional 100 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock valued at $128,000 after acquiring an additional 101 shares during the period. Finally, Lido Advisors LLC increased its holdings in ICU Medical by 4.5% in the 4th quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock worth $354,000 after acquiring an additional 106 shares in the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Trading Up 2.7%

NASDAQ:ICUI opened at $165.77 on Wednesday. The company has a market cap of $4.14 billion, a PE ratio of 89.61, a price-to-earnings-growth ratio of 2.26 and a beta of 0.76. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. The company has a 50 day simple moving average of $145.82 and a two-hundred day simple moving average of $139.89. ICU Medical has a 12 month low of $107.00 and a 12 month high of $167.99.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.19. The firm had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The company’s revenue was down 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Research analysts forecast that ICU Medical will post 6.51 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.